Table 2.
Hair Drug-Concentration by Virologic Outcome (N=227)
| Viral Suppression (N = 136) |
Viral Failure (N = 91) |
||||||
|---|---|---|---|---|---|---|---|
|
|
|||||||
| ART Analyzed |
Na | Median concentration (ng/mg) |
IQR | Na | Median concentration (ng/mg) |
IQR | pb |
| ATV | 5 | 7.09 | (2.30–7.12) | 8 | 2.06 | (0.75–3.22) | 0.11 |
| LPV | 28 | 9.72 | (6.32–16.10) | 22 | 0.53 | (0.23–1.42) | < 0.001 |
| RTVc | 33 | 0.84 | (0.61–1.27) | 30 | 0.14 | (0.03–0.51) | < 0.001 |
| EFV | 53 | 4.85 | (3.11–8.47) | 33 | 0.98 | (0.24–3.65) | < 0.001 |
| NVP | 50 | 54.85 | (41.90–75.30) | 28 | 34.35 | (13.55–59.80) | < 0.001 |
Viral Failure: HIV-1 RNA >400 copies/mL; ART, antiretroviral therapy; IQR, interquartile range; ATV, Atazanavir; LPV, Lopinavir; RTV, Ritonavir; EFV, Efavirenz; NVP, Nevirapine;
a
The total exceeds 136 and 91 for viral suppression and viral failure, respectively, due to the use of a combination pill of RTV with either ATV (ATV/r) or LPV (LPV/r);
b
Wilcoxon rank sum test;
c
RTV is the booster drug administered as a combination pill for both ATZ/r and LPV/r.